149 Medical
149 Medical is dedicated to improving outcomes for premature infants through innovative, life-changing technology. Their primary focus is on reducing morbidity and mortality by providing continuous, real-time monitoring of cerebral blood flow to detect and mitigate risks such as ventricular hemorrhage. Their flagship device, NIRDS1, is a non-invasive intracranial blood flow sensor validated in over 1,000 children, currently in clinical evaluation, and licensed exclusively from Massachusetts General Hospital. The company's mission is to shift the standard of care from traditional, less effective methods to advanced, early detection technologies, ultimately decreasing disabilities and improving long-term health outcomes for the smallest and most vulnerable patients.
Industries
Nr. of Employees
small (1-50)
Products
Continuous non‑invasive cerebral blood flow monitor (clinical prototype)
A clinical‑stage, non‑invasive optical monitoring system designed to provide continuous real‑time measurements of cerebral blood flow in premature infants to give clinicians an early warning of flow fluctuations associated with intraventricular hemorrhage risk.
Continuous non‑invasive cerebral blood flow monitor (clinical prototype)
A clinical‑stage, non‑invasive optical monitoring system designed to provide continuous real‑time measurements of cerebral blood flow in premature infants to give clinicians an early warning of flow fluctuations associated with intraventricular hemorrhage risk.
Expertise Areas
- Neurophotonics and optical brain monitoring
- Neonatal clinical monitoring and NICU study conduct
- Medical device design and commercialization
- Clinical validation and comparative physiological testing
Key Technologies
- Diffuse correlation spectroscopy (DCS)
- Near‑infrared spectroscopy (NIRS) principles
- Laser speckle / speckle contrast optical sensing
- Coherent light optical probe hardware
News & Updates
Wu et al., 2021, validated diffuse correlation spectroscopy measures of critical closing pressure against transcranial Doppler ultrasound in stroke patients.
Giovanella et al., 2020, validated diffuse correlation spectroscopy against ¹⁵O-water PET for regional cerebral blood flow measurement in neonatal piglets.
Bangalore-Yoganda et al., 2018, measured skeletal muscle blood flow during exercise using diffuse correlation spectroscopy and Doppler ultrasound.
Proctor et al., 2018, validated diffuse correlation spectroscopy sensitivity to nicotinamide-induced blood flow elevation in the murine hindlimb.
Buckley et al., 2012, validated diffuse correlation spectroscopic measurement of cerebral blood flow using MRI.
Carp et al., 2010, validated diffuse correlation spectroscopy measurements of rodent cerebral blood flow with MRI.
Wu et al., 2021, validated diffuse correlation spectroscopy measures of critical closing pressure against transcranial Doppler ultrasound in stroke patients.
Giovanella et al., 2020, validated diffuse correlation spectroscopy against ¹⁵O-water PET for regional cerebral blood flow measurement in neonatal piglets.
Bangalore-Yoganda et al., 2018, measured skeletal muscle blood flow during exercise using diffuse correlation spectroscopy and Doppler ultrasound.
Proctor et al., 2018, validated diffuse correlation spectroscopy sensitivity to nicotinamide-induced blood flow elevation in the murine hindlimb.
Buckley et al., 2012, validated diffuse correlation spectroscopic measurement of cerebral blood flow using MRI.
Carp et al., 2010, validated diffuse correlation spectroscopy measurements of rodent cerebral blood flow with MRI.